转移性肾细胞癌同步放疗与卡博替尼的真实世界实践模式与安全性:国际转移性肾细胞癌数据库联盟结果
这项国际多中心回顾性研究纳入2014至2020年接受卡博替尼治疗的127例转移性肾细胞癌患者,53%在放疗期间同步使用卡博替尼,放疗后90天内3-4级不良事件发生率为6.3%,无5级事件,仅1例非同步组患者因疑似放射性脑水肿相关肌无力住院。
要点
- 127例中53%在放疗日同步使用卡博替尼,3-4级不良事件6.3%(8/127),无5级事件。
- 常规姑息放疗中同步组3-4级不良事件6.3%(3/48)vs 非同步组5.0%(2/40)。
- 立体定向消融放疗中同步组3-4级不良事件3.6%(1/28)vs 非同步组9.1%(2/22)。
核心结论
- 在转移性肾细胞癌接受卡博替尼治疗的真实世界研究中,53%的患者同步接受放疗,放疗后90天内3-4级不良事件报告较少。
- 放疗与卡博替尼的联合使用需对患者和疾病特征进行风险-获益评估以优化治疗方案。
研究设计与样本
- 国际多中心回顾性研究,纳入2014至2020年接受任何线卡博替尼治疗且在卡博替尼开始前30天至停药后30天内接受放疗的转移性肾细胞癌患者。
- 共纳入127例连续患者,同步使用定义为在任何放疗疗程的放疗日使用卡博替尼。
主要发现
- 127例中67例(53%)在放疗日同步使用卡博替尼,其余患者在放疗日暂停卡博替尼。
- 总体3-4级不良事件发生率为6.3%(8/127),未观察到5级事件。
- 常规姑息放疗患者(n=88)中,同步组3-4级不良事件为6.3%(3/48),非同步组为5.0%(2/40)。
- 立体定向消融放疗患者(n=50)中,同步组3-4级不良事件为3.6%(1/28),非同步组为9.1%(2/22)。
- 非同步组1例患者在多发脑转移立体定向消融放疗后19天因疑似相关血管源性水肿所致肌无力而住院,无患者因放疗相关毒性住院。
关键数值与推荐
- 大多数患者为透明细胞组织学(88%),国际转移性肾细胞癌数据库联盟中危疾病(57%),且接受过至少一线既往治疗(93%)。
临床怎么用
- 原文结论指出放疗与卡博替尼的联合使用需对患者和疾病特征进行风险-获益评估以优化治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a paucity of data on the safety of cabozantinib use in combination with radiotherapy. OBJECTIVE: To report the practice patterns, safety, and efficacy of cabozantinib with radiotherapy in metastatic renal cell carcinoma (mRCC). DESIGN, SETTING, AND PARTICIPANTS: An international multicenter retrospective study was conducted. Patients with mRCC treated with cabozantinib at any line of therapy and who received radiotherapy between 30 d prior to the start date of cabozantinib and 30 d following discontinuation of cabozantinib, from 2014 to 2020, were included. Concurrent use was defined as the use of cabozantinib on radiotherapy treatment days during any course of radiotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcomes of interest were the rate of grade ≥3 adverse events (AEs) occurring within 90 d of receipt of radiotherapy. Secondary outcomes included hospitalization rate and patterns of cabozantinib and radiotherapy use. Baseline characteristics and AEs were presented descriptively. RESULTS AND LIMITATIONS: A total of 127 consecutive patients were included. Most patients had clear cell histology (88%), had International Metastatic Renal Cell Carcinoma Database Consortium intermediate-risk disease (57%), and had received at least one prior line of therapy (93%). Of 127 patients, 67 (53%) received concurrent cabozantinib with radiotherapy, while the remaining held cabozantinib on radiotherapy days. Overall, grade 3-4 AEs occurred in 6.3% (n = 8/127) of patients. No grade 5 events were observed. In patients treated with conventional palliative radiotherapy (n = 88), the rate of grade 3-4 AEs in those who had concurrent versus those who had nonconcurrent cabozantinib was 6.3% (n = 3/48) versus 5.0% (n = 2/40). No patient was hospitalized due to radiotherapy-related toxicity. In patients treated with stereotactic ablative body radiotherapy (SABR; n = 50), the rate of grade 3-4 AEs in those who had concurrent versus those who had nonconcurrent cabozantinib was 3.6% (n = 1/28) versus 9.1% (n = 2/22). One patient in the nonconcurrent group was hospitalized due to muscle weakness suspected to be related to associated vasogenic edema 19 d after SABR for multiple brain metastases. CONCLUSIONS: In this real-world study of patients with mRCC treated with cabozantinib, 53% of patients received radiotherapy concurrently, with few grade 3-4 AEs reported within 90 d of receiving radiotherapy. The use of radiotherapy and cabozantinib requires a risk-benefit assessment of patient and disease characteristics to optimize therapy regimens. PATIENT SUMMARY: Our study reports the real-world experience of using radiotherapy in patients receiving cabozantinib for metastatic kidney cancer. Over half of the patients continued taking cabozantinib while receiving radiotherapy, and few patients developed serious side effects. The combined use of radiotherapy and cabozantinib requires a careful risk-benefit assessment to achieve optimal treatment outcomes.
引用
- Loo Gan C, Huang J, Pan E, et al. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2022. PMID: 36328934. doi:10.1016/j.euo.2022.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。